ENTX
Entera Bio Ltd.
$1.70
+0.01 (+0.59%)
At close · Jul 9
Market Cap
$80.24M
Shares
49,225,321
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.70
Open$1.71
Day$1.62–1.72
52W$0.91–3.22
Avg vol 30d2.0M
Short int160K · 0.3% float · 2.9d
Short vol30%
Last earningsApr 20, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 8
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Neutral
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+1%
above
Price vs 50-day avg
+28%
above
RSI (14)
65
neutral
MACD trend
Positive
52-week position
34%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+44%
trailing
6-month return
+4%
trailing
YTD return
−12%
this year
Relative strength
−3%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+18% holders QoQ · +8 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.33% of float · ▼ -9.9% MoM · 2.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
26 holders — near 3-yr high, broad support
Squeeze score
51
elevated · 0–100
Fundamentals
Revenue growth
−77%
Y/Y
Gross margin
0%
contracting
EPS growth
0%
Y/Y
Free cash flow
$-7.5M
Valuation
P/E 6.3
below peers
Balance sheet
$7.1M
net cash
Quant / Vol
risk profile
Volatility
89%
annualized · 1-yr
Max drawdown
−68%
past year
ATR
10.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
May 11, 2028
Est · unconfirmed
· in 96 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+1%
Bullish
Price vs 50-day avg
+28%
Bullish
RSI (14)
65
Neutral
MACD trend
Positive
Bullish
52-week position
34%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+18% holders QoQ · +8 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.33% of float · ▼ -9.9% MoM · 2.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
26 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $2 · 34%
52-wk high $3
vs 200-day avg +1%
vs 50-day avg +28%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENTX
this stock
Entera Bio Ltd.
|
$80.24M | -12.4% | -76.8% | 6.3 | 0.3% |
|
ONC
BeOne Medicines Ltd.
|
$437.67B | -0.6% | +22179.2% | 890.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.01B | +9.9% | +46.2% | 29.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.03B | -14.0% | +20.8% | 16.3 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
26
- % held
- 16.0%
- Net QoQ
- -1.5M sh
- Top holder
- Knoll Capital Management,…
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENTX | +0.6% | +43.8% | +4.3% | -4.0% | -12.4% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +0.8% | +43.0% | -3.2% | -3.8% | -21.7% |